Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

10 Best Performing Pharma Stocks in 2025

Page 1 of 9

In this article, we will look at the 10 Best Performing Pharma Stocks in 2025.

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook. He stated that M&A activity started off strong in the year, and that pharma stocks are set to take off in 2026.

In addition to the big pharma companies, he believes that biotech, which had a really tough past 3-4 years, is ready to take off as well. These trends are partly due to M&A and the drug-pricing overhang passing. He expects cardiometabolic and obesity drugs, along with cardiovascular and oncology, to be the primary categories of interest for the main players in the domain for acquisitions.

READ ALSO: 14 Best Major Stocks to Invest in Right Now and 13 Best Strong Buy Stocks to Invest in Right Now.

The trends, therefore, point to a green light for M&A, according to Yee, with the biggest patent cliffs happening in 2028 and 2029. The big pharma companies have the largest balance sheets and patent cliffs they have ever had, which is why he expects the trends to pick up in 2026.

With these optimistic trends in view, let’s look at the 10 best performing pharma stocks in 2025.

Our Methodology

We used Finviz to screen pharma stocks and selected the best performers based on their one year performance. We also included the number of hedge fund holders for each stock as of Q3 2025, and sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of the 1-year performance.

Note: All data was recorded on January 8.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

10 Best Performing Pharma Stocks in 2025

10. Biogen Inc. (NASDAQ:BIIB)

1-Year Performance: 20.95%

Number of Hedge Fund Holders: 59

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to $190 from $142 but maintained a Hold rating, telling investors in a research note that while it updated its model, the fundamental views remain the same as 2025.

The same day, Biogen Inc. (NASDAQ:BIIB) also received rating updates from Goldman Sachs and Mizuho. Goldman Sachs raised the price target on the stock to $225 from $197 while keeping a Buy rating on the shares. It expects momentum to continue in 2026 after strong sector performance in 2025, supported by improving fundamentals, market dynamics, and easing policy risks. These factors, along with their secondary effects such as M&A, persist, according to the firm.

Mizuho, on the other hand, lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $207 from $177 and maintained an Outperformed rating, stating that it updated the company’s model since 2026 is “looking a bit better” for Biogen Inc. (NASDAQ:BIIB).

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases across the globe. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). The company has an elaborate marketed product portfolio for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. It also markets SPINRAZA to treat SMA, SKYCLARYS for the treatment of Friedreich’s Ataxia, and other drugs.

9. AbbVie Inc. (NYSE:ABBV)

1-Year Performance: 26.15%

Number of Hedge Fund Holders: 93

AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer Perform from Outperform on January 8 by Wolfe Research without a price target. The firm stated that the shares already reflect outperformance expectations in Skyrizi and Rinvoq, which is why it is moving to the sidelines waiting for higher visibility on the company’s immunology and inflammation “encore” and competitive dynamics.

In a separate development, Reuters reported on January 7 that AbbVie Inc. (NYSE:ABBV) denied its involvement in talks for the acquisition of Revolution Medicines. The update came after the Wall Street Journal reported that AbbVie Inc. (NYSE:ABBV) was in advanced discussions to buy Revolution Medicines, the cancer-drug developer. AbbVie Inc. (NYSE:ABBV) told Reuters in an emailed statement that it “is not in discussions with Revolution Medicines”.

The same day, UBS assumed coverage of AbbVie Inc. (NYSE:ABBV) with a Neutral rating, lifting the price target on the stock to $240 from $220. It told investors that it believes the company is fairly priced at current levels, and sees a balanced risk/reward for the company’s shares as competition emerges for its blockbuster immunology drugs Skyrizi and Rinvoq in 2026 and 2027.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

Page 1 of 9

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

 

Wall Street calls this $3 stock a “Melting Ice Cube.” They said the same thing about BTI before it returned 90%.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.